Skip to content

Study in Patients With COPD

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00215423
Enrollment
49
Registered
2005-09-22
Start date
Unknown
Completion date
2005-09-30
Last updated
2010-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease, COPD

Keywords

COPD, Chronic Obstructive Pulmonary Disease, Formoterol Fumarate, Formoterol

Brief summary

The purpose of this study is to determine which dose of the investigational drug is the most safe and effective for the treatment of COPD compared to the control drug

Interventions

DRUGFormoterol Fumarate

Sponsors

Dey
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
5 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of COPD * History of cigarette smoking

Exclusion criteria

* Clinical diagnosis of asthma * Significant pulmonary disease other than COPD * Other significant major organ disease(s)

Design outcomes

Primary

MeasureTime frame
Measure of lung function

Secondary

MeasureTime frame
Change in lung function, as well as vital signs
Physical Exam results, adverse event reporting, etc

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026